Image not available

Cicerello E et al, 2012: Management of Clinically Insignificant Residual Fragments following Shock Wave Lithotripsy

Cicerello E, Merlo F, Maccatrozzo L
Unità Complessa di Urologia, Ospedale Regionale Ca'Foncello, Treviso, Italy


Abstract

Clinically insignificant residual fragments (CIRFs) are small fragments (less than 5 mm) that are present in upper urinary tract at the time of regular post-SWL followup. The term is controversial because they may remain silent and asymptomatic or become a risk factor for stone growth and recurrence, leading to symptomatic events, and need further urologic treatment. Although a stone-free state is the desired outcome of surgical treatment of urolithiasis, the authors believe that the presence of noninfected, nonobstructive, asymptomatic residual fragments can be managed metabolically in order to prevent stone growth and recurrence. Further urologic intervention is warranted if clinical indications for stone removal are present.

Adv Urol. 2012;2012:320104. doi: 10.1155/2012/320104. Epub 2012 May 31
PMID: 22701479 [PubMed - in process]

Rate this blog entry:
0
 

Comments 1

Peter Alken on Friday, 03 February 2012 07:28

52 references accompany this review which collects what is known about the topic. It would have been more informative for the reader if the authors would have offered analysis of conflicting data like why the regrowth rates in the literature vary between 2, 1% and 59%. In the current EAU guideline on urolithiasis the recommendations for the treatment of residual fragments are accompanied by the lowest levels of evidence (LE: 4) and grade of recommendation (GR: C). There is still work do be done.

Peter Alken

52 references accompany this review which collects what is known about the topic. It would have been more informative for the reader if the authors would have offered analysis of conflicting data like why the regrowth rates in the literature vary between 2, 1% and 59%. In the current EAU guideline on urolithiasis the recommendations for the treatment of residual fragments are accompanied by the lowest levels of evidence (LE: 4) and grade of recommendation (GR: C). There is still work do be done. Peter Alken
Guest
Friday, 26 May 2017
STORZ MEDICAL AG
Lohstampfestrasse 8
8274 Tägerwilen
Switzerland
Tel.: +41 (0)71 677 45 45
Fax: +41 (0)71 677 45 05

www.storzmedical.com
Personal data
Address
Contact data
Message